Abstract 15P
Background
Estrogen plays a pivotal role in the development of breast cancer. Previous studies have shown that estrogen enhances cell proliferation via regulating its target gene expression in human breast cancer MCF-7 cell line. Although the effect of estrogen on the carcinogenesis in breast, the effects of pregnenolone (PG), an inactive precursor of estrogen, on MCF-7 cells or breast cancer have not been adequately explored. PG is a precursor in the biosynthesis of most of the steroid hormones containing estrogen. This investigation aimed to evaluate the effects of PG on cell proliferation and cell cycle-related protein expression.
Methods
We used Michigan Cancer Foundation-7 cell (MCF-7 cell) line, to assess the impact of PG on the carcinogenicity of breast cancer cells. We examined cell proliferation, survival rate and mobility using Bromodeoxyuridine, MTT assay and western blot. To reveal the mechanism of PG, we performed RNA seq after treatment of PG in the MCF-7 cells and transfection using siRNA of estrogen receptor and ERE luciferase vector.
Results
PG increased cell proliferation, viability, mobility, and the expression of proteins associated with the cell cycle, such as CDK2, CDK4, and Cyclin D1. We elucidated the carcinogenic mechanism of PG. Through protein-ligand docking energy analysis, we measured the affinity of PG for estrogen receptors (ERs), showing a high affinity for ERα similar to E2. When treated with cyanine 5-conjugated with PG (Cy5-PG), we observed that PG entered the cells within five minutes. Then, activated ERα entered the nucleus, bound to ERE-promoters, and significantly increased the expression of target genes associated with cell proliferation and carcinogenicity, such as pS2 and Ki-67. These results indicate that PG increases the expression of target genes through ERα and thereby affects the carcinogenicity of breast cancer cells.
Conclusions
Our results demonstrate that PG can have a significant impact on the proliferation and migration of ERα-positive breast cancer cells through ERα. Furthermore, the sustained high concentration of PG, unlike E2 which rapidly decreases after menopause, is strongly associated with the development of breast cancer. Therefore, PG has the potential to serve as a risk factor and diagnostic biomarker for breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract